



Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14

May 7, 2019

LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2019 financial results and operational highlights before open of U.S. markets on Tuesday, May 14, 2019.

Management will host a conference call at 8:30 a.m. ET/1:30 p.m. BST the same day to discuss the company's financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to: <https://www.autolus.com/investor-relations/news-events/events>.

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 7358198. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID 7358198.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: <https://www.autolus.com>.

Investor contact:

S.A. Noonan Communications
Susan A. Noonan
+1-212-966-3650
susan@sanoonan.com

Media Contacts:

Silvia Taylor
Vice President, Corporate
Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com

Julia Wilson
JW Communications
+44 (0) 7818 430877
j.wilson@autolus.com

Source: Autolus Therapeutics plc